Literature DB >> 22562529

Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly.

Dan Niculescu1, Mariana Purice, Mihail Coculescu.   

Abstract

In normal subjects growth hormone (GH) and insulin-like growth factor-I (IGF-I) have opposing effects on glucose metabolism. Active acromegaly is associated with insulin resistance (IR) and glucose intolerance although both GH and IGF-I are elevated. Our objective was to compare whether GH or IGF-I correlates more closely with IR and glucose intolerance in acromegaly. Basal serum IGF-I and GH, glucose and insulin during an oral glucose tolerance test were measured in 70 normoglycemic and 44 hyperglycemic acromegalic patients (21 impaired fasting glucose, 11 impaired glucose tolerance and 12 diabetes mellitus) according to American Diabetes Association criteria. 55 patients were assessed before any treatment for acromegaly and 59 after surgery and/or radiotherapy (15 patients had normal IGF-I after treatment). Patients treated with somatostatin analogs, GH-receptor antagonists or antidiabetic drugs were excluded. IR was assessed by various basal and stimulated indices. Homeostatic Model Assessment 2-Insulin Resistance (HOMA2-IR) index correlated more closely with IGF-I (r = 0.65, p < 0.0001) than nadir (r = 0.23, p = 0.008) or random GH (r = 0.26, p = 0.002). HOMA2-IR correlated better with IGF-I than nadir or random GH also in normoglycemic (n = 70; r = 0.74, p < 0.0001 vs. r = 0.36, p = 0.001 vs. r = 0.39, p < 0.001) and hyperglycemic patients (n = 44; r = 0.54, p = 0.0002 vs. r = 0.09, p = 0.4 vs. r = 0.14, p = 0.26). In multivariate logistic regression analysis IGF-I but not GH was a significant risk factor for glucose intolerance after adjusting for age, sex, weight and acromegaly duration (OR = 1.56, p = 0.01). In acromegaly IGF-I correlates more closely than GH with IR. IGF-I levels but not GH are associated with glucose intolerance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22562529     DOI: 10.1007/s11102-012-0396-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  30 in total

1.  Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose.

Authors:  Hisayo Yokoyama; Masanori Emoto; Shigehiko Fujiwara; Koka Motoyama; Tomoaki Morioka; Miyoko Komatsu; Hideki Tahara; Hidenori Koyama; Tetsuo Shoji; Masaaki Inaba; Yoshiki Nishizawa
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

2.  Correct homeostasis model assessment (HOMA) evaluation uses the computer program.

Authors:  J C Levy; D R Matthews; M P Hermans
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

3.  Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.

Authors:  S Kasayama; M Otsuki; M Takagi; H Saito; S Sumitani; H Kouhara; M Koga; Y Saitoh; T Ohnishi; N Arita
Journal:  Clin Endocrinol (Oxf)       Date:  2000-05       Impact factor: 3.478

4.  Limited value of the homeostasis model assessment to predict insulin resistance in older men with impaired glucose tolerance.

Authors:  C M Ferrara; A P Goldberg
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

5.  Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation.

Authors:  Samira Benyoucef; Katharina H Surinya; Dirk Hadaschik; Kenneth Siddle
Journal:  Biochem J       Date:  2007-05-01       Impact factor: 3.857

6.  AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects.

Authors:  Marie Bex; Roger Abs; Guy T'Sjoen; Jean Mockel; Brigitte Velkeniers; Katja Muermans; Dominique Maiter
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

Review 7.  Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

Authors:  Antonino Belfiore; Francesco Frasca; Giuseppe Pandini; Laura Sciacca; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2009-09-14       Impact factor: 19.871

8.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice.

Authors:  Shoshana Yakar; Jennifer Setser; Hong Zhao; Bethel Stannard; Martin Haluzik; Vaida Glatt; Mary L Bouxsein; John J Kopchick; Derek LeRoith
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

9.  Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin.

Authors:  D Kerr; W V Tamborlane; F Rife; R S Sherwin
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

10.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

View more
  12 in total

1.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors:  Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

Review 2.  Diabetes in Patients With Acromegaly.

Authors:  A M Hannon; C J Thompson; M Sherlock
Journal:  Curr Diab Rep       Date:  2017-02       Impact factor: 4.810

3.  Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.

Authors:  R Helseth; S M Carlsen; J Bollerslev; J Svartberg; M Øksnes; S Skeie; S L Fougner
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

4.  A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.

Authors:  Roberto Salvatori; Murray B Gordon; Whitney W Woodmansee; Adriana G Ioachimescu; Don W Carver; Beloo Mirakhur; David Cox; Mark E Molitch
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

5.  Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients.

Authors:  Orsalia Alexopoulou; Marie Bex; Peter Kamenicky; Augustine Bessomo Mvoula; Philippe Chanson; Dominique Maiter
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

6.  HOMA-IR in acromegaly: a systematic review and meta-analysis.

Authors:  Betina Biagetti; Anna Aulinas; Anna Casteras; Santiago Pérez-Hoyos; Rafael Simó
Journal:  Pituitary       Date:  2020-10-21       Impact factor: 4.107

7.  Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels.

Authors:  K Mori; Y Iwasaki; Y Kawasaki-Ogita; S Honjo; Y Hamamoto; H Tatsuoka; K Fujimoto; H Ikeda; Y Wada; Y Takahashi; J Takahashi; H Koshiyama
Journal:  J Endocrinol Invest       Date:  2013-05-10       Impact factor: 4.256

8.  Increased Risk of Persistent Glucose Disorders After Control of Acromegaly.

Authors:  Claire Rochette; Thomas Graillon; Frederique Albarel; Isabelle Morange; Henry Dufour; Thierry Brue; Frederic Castinetti
Journal:  J Endocr Soc       Date:  2017-11-24

9.  Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy.

Authors:  Thierry Brue; Anders Lindberg; Aart Jan van der Lely; Ann Charlotte Akerblad; Maria Koltowska-Häggström; Roy Gomez; Michael Droste; Judith Hey-Hadavi; Christian J Strasburger; Cecilia Camacho-Hübner
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

10.  Postoperative Changes in Metabolic Parameters of Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure Criteria.

Authors:  Masanori Yonenaga; Shingo Fujio; Mika Habu; Hiroshi Arimura; Takaaki Hiwatari; Shunichi Tanaka; Yasuyuki Kinoshita; Hiroshi Hosoyama; Hirofumi Hirano; Kazunori Arita
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-02-23       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.